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of the ones having atherosclerotic vascular disease, 13-
47% show moderate to intermediate hyperhomocyste-
ine levels [1,2].
Changes in plasma homocysteine levels can result 
from the presence of several factors including physio-
logical, genetic, nutritional, drug induced and hormonal 
factors. First studies indicating mild hyperhomocyste-
inemia as an independent risk factor for cardiovascular 
disease, with a prevalence of approximately 5% in the 
general population, date from the 80th decade [3-6].
Metabolism of Homocysteine
Homocysteine is an amino acid with SH group, pro-
duced exclusively from methionine which, as an essen-
tial amino acid, comes from food diet [7]. Homocysteine 
metabolism involves two different metabolic pathways: 
the remethylation and the transsulfuration pathways 
(Figure 1) [8,9].
The remethylation pathway, mainly occurring in 
starvation conditions, involves the catabolism of me-
thionine. In the first step, methionine reacts with ATP 
leading to the formation of S-adenosylmethionine. This 
molecule then loses the methyl group attached with 
the sulphur atom (present in methionine), forming 
S-adenosyl-homocysteine. The methyl group released 
by S-adenosylmethionine can be transferred by meth-
yl-transferases to several substrates (methyl acceptors) 
like proteins, DNA or phospholipids (Figure 1).
The next step is the hydrolysis of S-adenosyl-homo-
cysteine to produce homocysteine. Later, the sulphur 
atom of homocysteine can be transferred to serine en-
tering the transsulfuration pathway described below. 
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Introduction
Cardiovascular diseases are the main cause of death 
in developed countries. Several risk factors are involved 
in its development like family background, hypercholes-
terolemia, obesity, diabetes mellitus and environmental 
factors such as sedentarism. High level of plasma ho-
mocysteine also represents a risk factor, independent 
of other factors. It is observed that 5-7% of general 
population show hyperhomocysteinemia, and of those, 
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sequentially involved: Cystathionine β-synthase (CBS) 
and cystathionine lyase. The active form of vitamin B6 - 
pyridoxal phosphate - is a cofactor of CBS that converts 
homocysteine into cystathionine, first step of the trans-
sulfuration pathway (Figure 1). The α-ketobutirate can 
be converted into propionyl-CoA that is further trans-
formed into succinyl-CoA (an intermediate of the Krebs 
cycle). It is evident the importance of B vitamins in ho-
mocysteine metabolism, since these molecules play a 
crucial role as enzyme cofactors. Vitamin B6 is required 
for CBS activity while vitamin B12 is the cofactor of MS. 
Another important vitamin for homocysteine metabo-
lism is riboflavin that is necessary for MTHFR function.
Homocysteine can be found in plasma in the free 
form (around 20-30%), but most of it (70-80%) is associ-
ated with plasma proteins, mainly albumin.
Plasma homocysteine present in the free form can 
also be in the oxidized form, giving rise to two types 
of disulphides: Homocysteine dimers (homocystine) or 
homocysteine-cysteine dimers. From the free homocys-
teine fraction, 2 to 5% correspond to its reduced form. 
Total plasma homocysteine is the sum of all free forms 
and forms attached to proteins [11].
Concerning plasma homocysteine levels, there is no 
consensus about the upper standard limits for healthy 
Homocysteine can also be used to regenerate methi-
onine, by the vitamin B12 dependent enzyme methi-
onine synthetase (MS) that transfers a methyl group 
given by 5-methyltetrahydrofolate to homocysteine. 
In most cells, this is the main or unique pathway of 
conversion of homocysteine to methionine. This ami-
no acid will enter a new cycle of donation of methyl 
group. Another product of this reaction is tetrahydro-
folate, that will be reconverted to 5-methyltetrahydro-
folate through the folate cycle, where the conversion 
of 5,10-methylenetetrahydrofolate to 5-methyltetrahy-
drofolate is catalysed by the FAD dependent enzyme, 
methylenetetrahydrofolate reductase (MTHFR) [10]. 
MTHFR enzyme has an important function since it reg-
ulates the availability of 5-methyltetrahydrofolate for 
homocysteine remethylation. The reaction catalysed by 
MS allows the connection between the methionine and 
the folate cycles (Figure 1).
The transsulfuration pathway, that takes place in 
cases of methionine overload, involves the catabo-
lism of homocysteine to sulphate, later excreted in the 
urine. The sulphur atom present in homocysteine is 
transferred to serine leading to the production of cyste-
ine, while the nitrogenated group and the carbons that 
belonged to homocysteine are released as ammonium 
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Figure 1: Homocysteine metabolism (adapted from [10]).
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Li, et al. [25] detected eleven mutations and 
eight (IVS3+1G>A, p.T493fsX46, p.T236N, p.L230Q, p.
K72I, p.S201ProfsX36, p.M337IfsX115 and IVS14-1G>C) 
were novel. The remaining three mutations (p.R125Q, 
p.T257M and p.G116R) had been previously reported 
[25].
Moreover, Voskoboeva, et al. [26] detected one 
new nonsense mutation (Q368Term), one new mis-
sense mutation (р.D444Y) and three novel small dele-
tions (c.1560-1569delCACCGGGAAG; c.216-217delAT; 
c.1498-1499delT) in Russian patients.
Other rare genetic changes can cause an up to 20 
times increase in plasma homocysteine and lead to 
the development of severe hyperhomocysteinemia 
and result from deficiency in the MTHFR enzyme of 
the remethylation pathway and 10 different mutations 
in this gene have already been described (located at 
1p36.3) [18,19].
The major known genetic determinant of mild hyper-
homocysteinemia in the general population is a thermo-
labile missense mutation, that leads to the change of al-
anine per valine, resulting from the substitution of cyto-
sine per thymine in base 677 of the gene. This mutation 
leads to loss of more than 60% of MTHFR enzymatic ac-
tivity [20], and 8% of general population is homozygous 
for this variant. In these patients, folate level interferes 
directly with plasma homocysteine content, and this is 
only increased when folate concentration is below 15.4 
nmol/L [27-30]. This mutation can be present together 
with the CBS mutation.
The other rare genetic change results from mutation 
in the MS gene, being associated with ischemic cardiac 
disease, mainly in smokers [20].
In most cases, severe hyperhomocysteinemia de-
velops in patients homozygous for the CBS mutation 
and in only in 5-10% of individuals deficient in MTHFR. 
Heterozygous individuals for CBS and MTHFR deficien-
cies, when associated with low level of folate and use of 
drugs develop moderate or intermediate hyperhomo-
cysteinemia [18].
Mutations in the genes MTHFR and MS lead to clin-
ical symptoms like the ones described for the CBS mu-
tations, suggesting that the presence of high levels of 
homocysteine might be the pathogenic factor involved 
in vascular complications [19].
Although innate errors of homocysteine metabolism 
previously described are very rare, hyperhomocyste-
inemia is relatively common in several populations. It 
is more common in men (21% above women) and in-
creases in women during menopause [28]. There is also 
an increase with age and, since elderly patients show 
bigger vitamin deficiency, hyperhomocysteinemia is, 
in this group of individuals, an important risk factor for 
coronary disease [29,30].
individuals, ranging from 5 to 15 µmol/L [2,12,13]. How-
ever, some studies have shown that an upper limit of 
15 µmol/L is too high in well-nourished populations 
without vitamin deficiencies [14]. Moreover, plasma 
homocysteine concentrations vary with age and gender 
[12,13].
It has been documented the existence of substan-
tial cardiovascular risk with plasma homocysteine lev-
els between 10 and 15 µmol/L. However, on the other 
hand, de Bree, et al. [15] observed that an increase of 
5 µmol/L in plasma homocysteine concentration, rises 
1.03 the risk of coronary heart disease mortality. These 
results do not support the idea of an influence of hy-
perhomocysteinemia in increased risk of cardiovascular 
disease [15].
Genetic Factors Involved in the Development 
of Hyperhomocysteinemia
The clinical syndrome homocystinuria, identified al-
most 60 years ago [16,17], is a disorder with autosomal 
recessive transmission. Phenotypic characteristics in-
clude thromboembolism and vascular occlusion, chang-
es in long bones, ocular displacement, mental retarda-
tion and varying degrees of neurological impairment 
[10,18,19].
Severe hyperhomocysteinemia is caused by rare ge-
netic defects in the remethylation or transsulfuration 
pathways. The most common inborn error of homo-
cysteine metabolism is the CBS deficiency, also called 
classical hyperhomocysteinemia, that affects the trans-
sulfuration pathway. Thirty-three point mutations in the 
long arm of chromosome 21 (21q22.3) responsible for 
this enzymatic deficiency have been described [20]. The 
incidence of homozygous individuals for the CBS muta-
tion in the world is 1:200.000, while for heterozygous 
varies between 1:70 and 1:2000 in the general popula-
tion [21]. According with Tsai, et al. [11], it is estimated 
that 30-40% of individuals with early vascular disease, 
are heterozygous for the CBS mutation.
So far, more than 150 different mutations in the 
CBS gene have been identified in different populations 
[22]. Examples of these mutations are nine distinct mu-
tations identified by Mendes, et al. [23] in 22 indepen-
dent alleles from homocystinuria patients: Four nov-
el mutations (p.K269del, p.P427L, p.S500L and p.L540Q) 
and five previously described mutations (p.P49L, 
p.C165Rfs*2, p.I278T, p.R336H and p.D444N). Another 
study identified two novel missense mutations (p.L136P 
and p.A158V), in the CBS gene of a Han Chinese family 
[22].
Two novel CBS mutations were identified in work 
of Ibrahim, et al. [24], a missense change in exon 7 
(p.L156P) and an in-frame deletion (c.808_810del; 
p.E270del) in exon 10. These researchers also identified 
a recurrent missense mutation (p.T257M) in exon 10 of 
the gene [24].
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Other work explored the contribution of nitrative 
stress on the deficiency of CBS activity [35]. This study 
observed that an increased nitrative stress level was ac-
companied by increased plasma homocysteine. More-
over, increased nitration of CBS led to decreased CBS 
activity [35].
Moreover, Yakub, et al. [36] observed a relationship 
between lead and homocysteine plasma levels. These 
researchers found out that individuals with genotype 
CT or TT for the MTHFR gene who also had blood lead 
levels above 10 µg/dL, had significantly increased risk 
for hyperhomocysteinemia when compared with the CC 
genotype [36].
Studies have also been conducted on the impor-
tance of microbial infection in homocysteine levels and 
consequent atherogenesis. Pathogenic microorganisms 
cause synthesis of polyamines in host cells. This is ac-
complished by increasing the transfer of aminopropyl 
groups from adenosylmethionine to putrescine, that 
leads to depletion of intracellular adenosylmethionine 
in those cells. Absence of adenosylmethionine dysreg-
ulates methionine metabolism, leading to hyperhomo-
cysteinemia, among other effects [37,38].
Pathomechanisms of Hyperhomocysteinemia 
in the Development of Cardiovascular Disease
Hyperhomocysteinemia has been considered an im-
portant risk factor, independent of other factors, for 
cardiovascular disease and atherosclerosis [39,40].
So far, there is no consensus concerning the patho-
physiological mechanism explaining the relationship 
between hyperhomocysteinemia and cardiovascular 
disease, and several hypotheses have been suggested. 
In this way, vascular lesion resulting from hyperhomo-
cysteinemia, would involve lesion of endothelial cells, 
growth of vascular smooth muscles, increase in platelet 
adhesion and oxidation of LDL followed by its deposi-
tion in the vascular wall and the activation of blood co-
agulation cascade [39,41].
Studies have also shown that high levels of homocys-
teine have impact on the traditional cardiovascular risk 
factors. For instance, hyperhomocysteinemia seems to 
influence plasma cholesterol levels. Choy, et al. [42,43] 
observed that high levels of homocysteine lead to in-
creased production of cholesterol and secretion of apo-
lipoprotein B-100. This effect on cholesterol synthesis 
is mediated by activation of the enzyme HMG-CoA re-
ductase, that catalyses the regulatory point in choles-
terol biosynthesis [42,43]. Wu, et al. [44] also observed 
a markedly increase in HMG-CoA reductase activity in 
liver cells of hyperhomocysteinemic rats, together with 
hepatic lipid accumulation. Activation of HMG-CoA re-
ductase was caused by increased gene expression and 
reduction in enzyme phosphorylation (that converts 
it in the inactive form) [44]. According to Choy, et al. 
[42] the increase in apoB secretion was caused by the 
Environmental Factors Determining the Devel-
opment of Hyperhomocysteinemia
Several studies discuss the effect of external factors 
in the development of high levels of plasma homocys-
teine. One of these factors are nutritional changes. 
Nygard, et al. [31] describe a strong inverse association 
between plasma concentration of folic acid and/or food 
diet and total concentration of plasma homocysteine 
[31]. Folic acid deficiency can lead to increased plasma 
homocysteine [31]. Individuals with folate levels above 
15 nmol/L do not show hyperhomocysteinemia [31].
Moreover, according with the study of Fonseca, et 
al. [7], patients with vitamin B6 deficiency, have normal 
basal homocysteine but altered levels after overload. 
However, other studies observed that folate, vitamin B6 
or B12 insufficiencies were associated with hyperhomo-
cysteinemia in both sexes [32]. On the other hand, de-
ficiency of vitamin B2 was significantly associated with 
hyperhomocysteinemia only in males. In individuals with 
adequate folate, vitamins B6 and B12 levels, there was 
no significant association between vitamin B2 and hy-
perhomocysteinemia [32]. The association was only ob-
served in individuals who had poor folate, vitamin B6, 
or B12 status [32]. Same researchers also observed that 
the association between vitamin B12 insufficiency and 
hyperhomocysteinemia was not affected by simultane-
ous vitamin B2 or B6 insufficiency but increased 3-fold 
when combined with folate deficiency [32].
These results suggest a synergic relationship of fo-
late and vitamin B12 deficiencies on the development of 
hyperhomocysteinemia. The same happens with folate 
and vitamin B6 insufficiencies [32].
The use of certain drugs can also indirectly lead to 
increase in plasma homocysteine. During therapy with 
methotrexate (structural analogue of folate) and anti-
convulsants (phenytoin and carbamazepine), folic acid 
levels are decreased [18] and can result in increase in 
homocysteine levels. This statement is consistent with 
work of Chandrasekaran, et al. [33] where a correlation 
between the duration of antiepileptic drug therapy and 
high homocysteine plasma levels was observed. How-
ever, a meta-analysis performed to determine the in-
fluence of oxcarbazepine monotherapy on plasma ho-
mocysteine levels, does not support the hypothesis that 
the therapy changes serum levels of homocysteine [34].
Moreover, the use of the anaesthetic nitrous oxide 
reduces vitamin B12 levels and vitamin B6 is altered 
by theophylline, consequently affecting homocysteine 
content [18].
Hormonal changes, like oestrogen decrease during 
menopause, increases homocysteine levels. Thyroid 
hormones also interfere with plasma homocysteine. It 
has been observed that patients with hypothyroidism 
show high homocysteine levels, while hyperthyroidism 
leads to normal levels [7].
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Studies have suggested that a better biomarker of 
the association of hyperhomocysteinemia and vascular 
disease would be the increase in S-adenosyl-homocys-
teine, instead of homocysteine itself [54,55]. The en-
hancement of S-adenosyl-homocysteine results from 
the reversal reaction catalysed by S-adenosyl-homocys-
teine hydrolase. The increase in S-adenosyl-homocyste-
ine leads to feedback inhibition of methyltransferases 
that are dependent on S-adenosylmethionine, like DNA 
methyl-transferases [54,55]. Therefore, there will be a 
decrease in DNA methylation. Results of Castro, et al. 
[53] support the hypothesis of S-adenosyl-homocyste-
ine accumulation and consequent DNA hypomethyl-
ation are the causing agents of the pathogenic role of 
hyperhomocysteinemia in vascular disease. These dis-
turbances in DNA methylation and consequent changes 
in gene expression, have deep effects in the risk of car-
diovascular disease [56].
In the same way, Zhang, et al. [57] observed that 
mild increased homocysteine levels induce hypomethyl-
ation, while high concentration of homocysteine lead to 
hypermethylation in the promoter CpG island of the di-
methylarginine dimethylaminohydrolase (DDAH2) gene. 
An increase in DDAH2 gene expression was observed in 
mild enhanced concentration and in high concentration 
of homocysteine a decrease in gene expression was de-
tected [57]. This protein is the key enzyme for degrada-
tion of asymmetric dimethylarginine (ADMA), which is 
an endogenous inhibitor of endothelial nitric oxide (NO) 
synthase (eNOS). The inhibition of DDAH2 activity was 
followed by increase in ADMA and consequent reduc-
tion of eNOS activity and decrease of NO production 
[57]. Dysfunction of nitric oxide pathway, resulting from 
hyperhomocysteinemia, that leads to reduced dilator 
responses of arteries and arterioles was proposed as 
one of the pathomechanisms that would affect all cell 
functions involved in cardiac dysfunction [58].
Yan, et al. [59] also showed that hyperhomocystein-
emia reduces NO levels, phosphorylation of endothelial 
nitric oxide synthase (eNOS) and vascular endothelial 
growth factor expression, leading to endothelial dys-
function.
Moreover, increased S-adenosyl-homocysteine leads, 
not only to DNA hypomethylation, but also to decreased 
methylation of tRNA [60], as well as to decreased pro-
tein arginine methylation [61]. Esse, et al. [61] state 
that protein arginine methylation is more sensitive to 
increases in S-adenosyl-homocysteine than DNA meth-
ylation.
Changes in tRNA methylation lead to altered expres-
sion of the selenoprotein glutathione peroxidase 1, one 
of the major antioxidants that can modulate overall ox-
idative stress [60]. The decrease in its gene expression 
leads to an increase in cellular hydrogen peroxide and 
consequent up-regulation of endothelial adhesion mol-
ecule expression. This is enough to provoke changes in 
increase in cholesterol level induced by homocysteine, 
being a plausible mechanism for the observed relation-
ship between hyperhomocysteinemia and the develop-
ment of atherogenesis and coronary artery disease.
Moreover, Hemati, et al. [45] observed that insu-
lin resistant patients usually have higher homocyste-
ine plasma level. This study allowed establishing a re-
lationship between high homocysteine levels and high 
plasma glucose observed in diabetes mellitus type 2 
patients [45].
Other studies have associated hyperhomocystein-
emia with increased blood pressure [46,47]. However, 
work of Borges, et al. [48] does not corroborate the 
possible role of homocysteine on changes in blood pres-
sure.
In vivo studies performed by Dudman [49] showed 
that homocysteine activates separately each type of 
leucocyte and endothelial cell, giving evidences of the 
role of homocysteine as a natural regulator of leuco-
cytes. Leucocyte induction and endothelial adhesion 
provoked by homocysteine, leads to trans-endothelial 
migration of leucocytes and endothelial lesion. Conse-
quently, selective change of the expression of the pro-
tein responsible for chemoattraction of monocytes and 
interleukins will take place. These lead to the release of 
cytokines and inflammatory agonists [49].
Study of Poddar, et al. [50] showed that homocyste-
ine induced mRNA expression of the proinflammatory cy-
tokines monocyte chemoattractant protein-1 and inter-
leukin-8 in cultured human aortic endothelial cells, and 
their secretion. This suggests that homocysteine may 
contribute to the initiation and progression of vascular 
disease by promoting leukocyte recruitment [50].
Moreover, Silverman, et al. [51] observed that hy-
perhomocysteinemia leads to a 5-fold increase in vascu-
lar cell adhesion molecule 1 (VCAM-1) mRNA expression 
in human endothelial cells, resulting in increased adhe-
sion of monocytes.
Fang, et al. [52] demonstrated that hyperhomocys-
teinemia and hyperglycemia increased monocytes and 
macrophages lesions, followed by increased levels of 
inflammatory monocytes and macrophages and conse-
quent accelerates atherosclerosis. Inflammatory mono-
cytes correlated negatively with the ratio of S-adenosyl-
methionine to S-adenosyl-homocysteine [52].
An alternative explanation for the effect of hyperho-
mocysteinemia is that it is a marker of low level of vita-
mins B or diminished capacity of methylation in cells, 
being any of these two factors possibly related with the 
disease. Castro, et al. [53] showed that leucocytes of pa-
tients with cardiovascular disease have decreased DNA 
methylation, together with increased plasma levels of 
homocysteine and S-adenosyl-homocysteine. More-
over, even with a general state of hypomethylation, 
certain regions of the genome can be hypermethylated.
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cludes that high homocysteine levels cause mitochon-
drial dysfunction, which was displayed as a significant 
decrease in respiratory chain activities, increased pro-
duction of reactive oxidative species and mitochondrial 
swelling [68].
Zhang, et al. [69] also observed, together with de-
creased activity of complex III, low levels of aconitase 
gene expression (enzyme involved in the Krebs cycle) in 
hyperhomocysteinemia conditions. Increased levels of 
reactive oxidative species and decreased ATP content, 
that play important roles in cellular stress response 
during cell growth, were also present [69]. Hyperho-
mocysteinemia induced mitochondrial dysfunction that 
modulated apoptosis [70], leading to coronary and pe-
ripheral artery and venous vessel diseases, resulting in 
vasomotor dysfunction and increased thrombosis, con-
sequently increasing morbidity and mortality [58].
Oxidative stress seems to be an important in vivo 
mechanism responsible for the development of endo-
thelium dysregulation of wall shear stress in hyperho-
mocysteinemia cases [58,71].
Increased oxidative species, decreased endothelial 
nitric oxide synthase and consequent reduced nitric ox-
ide levels were accompanied by reduced levels of pro-
tein S-nitrosylation in cases of hyperhomocysteinemia 
[72-74]. Results of these studies suggest that homocys-
teine promotes atherosclerosis by inhibiting vascular 
protein S-nitrosylation [72-74].
As previously discussed, infections by pathogenic mi-
crobes leads to depletion of adenosylmethionine that 
causes, besides hyperhomocysteinemia, a decrease 
in the production of nitric oxide and impaired host 
response to infectious microbes, contributing to the 
pathogenesis of dementia and atherosclerosis [37,38].
All mentioned changes, that result from hyperho-
mocysteinemia, impair endothelium-dependent vaso-
dilation and regulation of blood flow, apoptosis of en-
dothelial cell that can be an important mechanism of 
vascular injury, resulting in vascular leak, inflammation 
and coagulation, leading to the development of athero-
sclerosis and cardiovascular disease [75].
Treatment Approaches for Hyperhomocyste-
inemia
As previously described, 5-methyltetrahydrofolate 
is the substrate for the enzyme methionine synthetase, 
being produced from folic acid. A strong inverse associ-
ation between folate concentration and plasma homo-
cysteine has been described by Nygard, et al. [31].
One approach tested in several studies for the treat-
ment of hyperhomocysteinemia involves supplemen-
tation of folic acid. The study Homocysteine Lowering 
Trialist Collaboration [76] showed that supplements of 
0.5-5.0 mg/day of folic acid, lead to a decrease of 25% in 
plasma homocysteine.
cell adhesion by increasing the binding of leukocytes. 
This study demonstrates that an increase in S-adenos-
yl-homocysteine can result in oxidative stress [60].
Moreover, recent studies have suggested that alter-
ations in hydrogen sulfide (H2S) production may also con-
tribute to homocysteine associated vascular disease. H2S 
was found to be a gasotransmitter, like nitric oxide and 
carbon monoxide [62]. Production of H2S results from 
the activity of several enzymes, including CBS [63]. An al-
ternative reaction catalysed by CBS is the condensation 
of cysteine with homocysteine to form cystathionine and 
H2S [64,65]. Chen, et al. [65] have shown that at physi-
ologically relevant concentrations of serine, homocyste-
ine, and cysteine, about 5% of the cystathionine formed 
is from cysteine. S-adenosylmethionine stimulates H2S 
producing reaction [65]. H2S is produced in endothelium, 
participating in the regulation of endothelial integrity 
through its beneficial anti-inflammatory and antioxidant 
effects. Hence, hyperhomocysteinemia is usually associ-
ated with decreased levels of H2S and this may contribute 
to the development of atherosclerosis.
Another proposed mechanism is the simultaneous 
increase of the activity of thromboxane A2 (TXA2) both 
in vessels and platelets [58]. Koller, et al. [58] suggested 
that these changes result from an increased production 
of reactive oxidative species (oxidative stress) due to 
increased NADPH oxidase assembly, which eventually 
leads to an inflammatory process and morphological re-
modelling of vessels.
In cases of hyperhomocysteinemia, the increase in 
superoxide production by NADPH oxidase and reduced 
formation of NO alters the regulation of mitochondrial 
function in the myocardium [58,66].
According with Chen, et al. [67] severe oxidative 
stress may lead to cell death through apoptosis or ne-
crosis. Besides NADPH oxidase, there are other stim-
uli for the production of reactive oxidative species in 
cells that include mitochondria where, under oxidative 
stress, the free electrons on the mitochondrial electron 
transport chain may leak out and react with molecular 
oxygen, thereby generating superoxide anion as met-
abolic by-products during respiration. Moreover, NO 
may react with superoxide anions producing the highly 
reactive peroxynitrite anion that damage DNA, proteins 
and lipids. These alterations in macromolecules play an 
important role in many physiological and pathological 
conditions [67].
A recent study found that hyperhomocysteinemia 
caused mitochondrial ultrastructural injury, transloca-
tion of cytochrome c and inhibited the activities of com-
plexes I, II and III from the electron transport chain [68]. 
These researchers also observed an increase in reactive 
oxidative species levels together with enhanced mito-
chondrial pSTAT3, a transcription factor that regulates 
expression of many other genes involved in cell prolif-
eration, differentiation and survival [68]. This study con-
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Other studies show that vitamin B12, important co-
factor of the enzyme methionine synthetase, has lower 
effect in the decrease of plasma homocysteine, when 
compared with folic acid [76]. In this study, supplements 
of vitamin B12 (0.5 mg/day) allowed an additional de-
crease of 7% in plasma homocysteine [76]. Quilivan, et 
al. [83] observed that when folate levels are optimized, 
a dependence between vitamin B12 and plasma homo-
cysteine develops, that is not observed during folic acid 
supplementation.
Azadibakhsh, et al. [84] tested a combined treat-
ment of folic acid and vitamin B12 and concluded that 
oral supplementation with 15 mg/day folic acid togeth-
er with 1 mg/day of vitamin B12 is effective in reducing 
homocysteine levels in haemodialysis patients.
Supplements of pyridoxal phosphate, active form of 
vitamin B6 (cofactor of the enzyme cystathionine β-syn-
thetase) do not have any additional effect to folic acid 
and vitamin B12 supplementation [76]. However, work 
of McKinley, et al. [85] with healthy individuals between 
63-80 years old, showed that supplement of low dose 
of vitamin B6 (1.6 mg/day) for 12 weeks, after folic acid 
supplementation (that leads to 19.6% homocysteine 
reduction), leads to a subsequent decrease of 7.5% in 
plasma homocysteine levels.
No consensus is observed among the results ob-
tained in several studies with B vitamin supplementa-
tions. However, according with Debreceni and Debrece-
ni [86,87] the failure of vitamin therapies may result 
from inappropriate designs, since most studies neglect-
ed the impact of the use of other treatments, like statins, 
acetylsalicylic acid and other drugs, concomitant with B 
vitamin supplementations. These researchers state that 
the effect of statins and aspirin on cardiovascular dis-
ease protection and prevention might have reduced or 
abolished the possibility of observing an effect of B vita-
min supplementation. In this way, further research is re-
quired to evaluate the real effect of vitamin substitution 
therapy on decreasing homocysteine plasma levels and 
cardiovascular disease prevention [86,87].
Riboflavin supplements (required for the MTHFR en-
zyme) are not effective in plasma homocysteine reduc-
tion, before or after optimization of folate levels [88]. 
However, homozygous individuals for the C677T muta-
tion on the MTHFR gene show riboflavin dependence 
[89,90].
Moreover, Moat, et al. [91] measured plasma ho-
mocysteine in 126 healthy individuals 20-63 years of 
age with different MTHFR genotypes (42 CC, 42 CT, 
and 42 TT) at baseline and after three supplements for 
4 months: Placebo plus natural diet; 400 µg/day of fo-
lic acid supplement plus natural diet; and increased di-
etary folate to 400 µg/day. This study showed that at 
baseline and after nutritional intervention, lower ribo-
flavin status was associated with increased plasma ho-
mocysteine concentrations. Moreover, at baseline, in-
On the other hand, a study of Wald, et al. [77] in pa-
tients with cardiovascular disease, allowed to establish 
a food supplement of 0.8 mg/day to reach maximal drop 
of plasma homocysteine. Tighe, et al. [78] observed that 
a maximum homocysteine decrease in patients with 
cardiac disease, can be obtained with folic acid supple-
ments like the ideal dose for healthy individuals.
Malinow, et al. [1] observed a reduction of plasma 
homocysteine levels by using breakfast cereals fortified 
with folic acid in patients with coronary heart disease. 
These researchers showed that plasma homocysteine 
decreased proportionally with the increase in plasma 
content in folic acid and this one was affected by the 
folic acid content of the breakfast cereal [1]. Cereals 
providing 127 µg/day of folic acid, increased plasma fo-
lic acid by 31%, but decreased plasma homocysteine by 
only 3.7%. But cereals giving 499 and 665 µg/day of folic 
acid, increased plasma folic acid by 64.8% and 105.7%, 
respectively, and decreased plasma homocysteine by 
11% and 14%, respectively [1].
Fabre, et al. [79] also obtained a 32.3% reduction in 
plasma homocysteine by oral supplementation of 5 mg/
day of levofolinic acid to healthy women aged 18-35 years 
for 30 days. A decrease in plasma homocysteine was ob-
served from the second day of treatment onwards and 
maximum decline was seen after 30 days [79].
However, Armada, et al. [80] tested the supplemen-
tation of folic acid or folinic acid to haemodialysis pa-
tients and no normalization of homocysteine levels was 
observed.
A recent study of Tian, et al. [81] tested the efficacy 
of folic acid therapy in patients having hyperhomocyste-
inemia. After 3 months of treatment, plasma homocys-
teine levels of 484 patients were reduced to below the 
normal levels (15 μmol/L), corresponding to an average 
reduction of 56% [81]. However, these researchers ob-
served that more than 40% of patients subjected to folic 
acid supplementation failed to reach the normal homo-
cysteine range (5-15 μmol/L) after 3 months of treat-
ment [81].
Zappacosta, et al. [82] tested the efficacy of a fo-
late-rich diet or pharmacological supplementation of 
individuals with moderate hyperhomocysteinemia, on 
plasma homocysteine decrease. They observed that 
supplementation with natural folate-rich foods, folic 
acid or 5-methyltetrahydrofolate allowed a similar re-
duction in homocysteine levels in blood [82].
Similar results were obtained by Chandrasekaran, 
et al. [33] with supplementation of folic acid to hyper-
homocysteinemic children receiving phenytoin and 
carbamazepine monotherapy. These researchers ob-
served that the duration of antiepileptic drug therapy 
correlated significantly with high homocysteine and low 
folic acid plasma levels and administration of folic acid 
reduced plasma homocysteine content [33].
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and hepatic antioxidant status in rats fed with high me-
thionine diet [95]. This study reports that plasma homo-
cysteine increased after high methionine diet and quer-
cetin supplementation was able to lower those levels. 
However, this effect was accompanied by a decrease 
in serum and liver glutathione content and increased 
plasma alanine aminotransferase and aspartate amino-
transferase levels [95]. These authors suggest that one 
possible mechanism is associated with increased trans-
sulfuration of homocysteine, with quercetin acting as a 
prooxidant [95].
Several randomized control studies were conducted 
to examine whether homocysteine-lowering B-vitamin 
therapy would decrease the occurrence of adverse car-
diovascular events. Toole, et al. [96] observed that mod-
erate reduction of total homocysteine had no effect on 
vascular outcomes during the 2 years of follow-up.
Work of Towfighi, et al. [97] observed that age mod-
ified the association between B vitamin therapy and re-
current vascular risk in individuals having hyperhomo-
cysteinemia. In this study, older individuals were more 
likely to benefit from this therapy when compared with 
younger ones [97].
In the same way, a study of Nigwekar, et al. [98] in-
tended to evaluate the benefits and harms of some of 
the described homocysteine lowering therapies on all-
cause mortality and cardiovascular event rates in pa-
tients with end-stage kidney disease. Although these 
strategies can help in lowering plasma homocysteine 
levels, these researchers concluded that they did not 
reduce mortality (cardiovascular and all-cause) or car-
diovascular events among these patients.
Several meta-analysis studies have been published 
evaluating the impact of homocysteine-lowering inter-
ventions (vitamins B6, B9 and B12 supplementations) 
on cardiovascular events and observed no differences 
in effects of such interventions given alone or in combi-
nation on myocardial infarction, death from any cause 
or adverse events [99-102].
Conclusion
High level of plasma homocysteine is one of the risk 
factors contributing to cardiovascular disease. Plasma 
homocysteine content is influenced by diverse genetic 
and environmental factors. Several hypotheses con-
cerning the pathological mechanism of hyperhomocys-
teinemia have been proposed, but no clear picture has 
been established yet.
Hyperhomocysteine influences multiple vascular re-
sponses, including coagulation, platelet function, vascu-
lar smooth muscle responses, and endothelial function. 
This condition induces endothelial cell damage and al-
ters the production and/or activity of vasoregulatory 
mediators like NO. Moreover, high levels of plasma 
homocysteine impair endothelium-dependent vasodila-
dividuals with the TT genotype had significantly higher 
homocysteine levels than individuals with the CT and CC 
genotypes [91]. Plasma folate was lower in the TT group 
than in the CT or CC genotypes. CT individuals had in-
termediate levels [91]. Results of this study suggest that 
an increase in folic acid intake might also increase the 
requirement for riboflavin to achieve maximal catalytic 
activity of the enzyme MTHFR. However, no association 
between riboflavin status and vascular endothelial func-
tion at baseline or after increased intake from fortified 
foods was observed, suggesting that the increase in ri-
boflavin intake may not have additional benefits to the 
cardiovascular system [91].
A long-term treatment with vitamin C has been ap-
plied by Bagi, et al. [71] to rats having hyperhomocys-
teinemia to prevent oxidative stress-induced dysregu-
lation of arteriolar wall shear stress observed in these 
cases. Rats subjected to this treatment showed reduced 
oxidative stress and increase in nitric oxide bioavailabil-
ity. The regulation of shear stress in arterioles was re-
stored and systemic blood pressure normalized [71].
Other strategies have been tested for the treatment 
of hyperhomocysteinemia like the administration of 
cadmium in hyperhomocysteinemic mice, since this 
condition may result in susceptibility to xenobiotics 
like cadmium. In the study of Ramambason, et al. [92] 
no difference in plasma homocysteine level was found 
after cadmium administration in control and hyperho-
mocysteinemic mice. However, exposed hyperhomo-
cysteinemic mice showed significant lower levels of 
glutathione when compared to control mice, reflecting 
oxidative stress [92].
A recent study of Haddadi-Guemghar, et al. [93] used 
prune extract, a good source of phenolic antioxidants, 
to investigate its effect on hyperhomocysteinemic male 
mice. These researchers observed that the administra-
tion of prune extract significantly decreased plasma ho-
mocysteine level [93].
Kondakçi, et al. [94] tested the effect of N-acetylcys-
teine on plasma homocysteine levels and observed a de-
crease in serum homocysteine together with reduction 
of hepatic and renal reactive oxygen species. Studies of 
Chen, et al. [65] provide a biochemical explanation for 
the homocysteine-lowering effects of N-acetylcysteine 
treatment. Decreased H2S levels are found to be patho-
genic in human disease. In this way, it may be possible 
to increase H2S and lower homocysteine levels by in-
creasing the concentration of cysteine in tissues. N-ace-
tylcysteine is converted to cysteine inside cells, thereby 
increasing the concentration of cysteine and thus driv-
ing the conversion of homocysteine to cystathionine. 
This treatment would also increase the production of 
H2S [65].
Moreover, another study evaluated the effect of 
quercetin administration on homocysteine metabolism 
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tion and regulation of blood flow, endothelial cell apop-
tosis that will lead to the development of atherosclero-
sis and cardiovascular disease.
Treatment strategies aiming the decrease in homo-
cysteine levels have been tested and all point to the 
correction of coenzymes levels. These coenzymes are 
essential for maximum activity of enzymes with critical 
roles in homocysteine metabolism. Supplementations 
of folic acid and/or vitamins B (mainly B12, but also 
B6), precursors of the synthesis of the mentioned coen-
zymes, have been effective in reduction of high levels of 
homocysteine, in most populations. Another B vitamin, 
riboflavin, seems to have effect on homocysteine levels 
in individuals carrying the C677T mutation on the MTH-
FR gene.
The mechanism of the beneficial effects of folates on 
the endothelium remains unclear, however it might in-
clude antioxidant actions, effects on cofactor availabil-
ity, or direct interactions with the enzyme endothelial 
NO synthase [103].
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